Afshin Amirpour1, Mehrbod Vakhshoori2, Reihaneh Zavar1, Hadi Zarei3, Masoumeh Sadeghi1, Behzad Yavari1. 1. Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. 2. Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. 3. Chamran Hospital, Department of Critical Care Nursing, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
BACKGROUND: The probable impact of growth hormone (GH) as a heart failure (HF) treatment strategy is still less investigated. Therefore, we aimed to evaluate the relation of 3-month GH prescription on left ventricular ejection fraction (LVEF), interventricular septum (IVS), posterior left ventricle (LV) thickness, end systolic and end diastolic diameters (ESD and EDD), and pulmonary arterial pressure (PAP) among Iranian individuals suffering from HF due to MI attack. METHODS: A total of 16 clinically stable participants with HF diagnosis and LVEF < 40% were selected for enrollment in this pilot randomized double-blinded study. They were randomly assigned equally to groups received 5 IU subcutaneous GH or placebo. Injections were done every other day for a total of 3-month duration. After termination of intervention and nine months afterwards, cardiac outcomes were assessed. RESULTS: Baseline and 12-month posttrial participants' characteristics were similar. LVEF was increased significantly by three months started from baseline in individuals receiving GH (32 ± 3.80% to 43.80 ± 4.60%, P = 0.002). During the next 9 months of follow-up concurrent with cessation of injections, LVEF was declined (43.80 ± 4.60% to 32.20 ± 6.97%, P = 0.008). LVEF and ESD were remarkably higher and lower in GH group compared with controls by the end date of injections (43.80 ± 4.60% vs. 33.14 ± 4.84%, P = 0.02 and 39.43 ± 3.45 mm vs. 33 ± 3.16 mm, P = 0.03, respectively). No other considerable association was found in terms of other predefined variables in neither GH nor placebo groups. CONCLUSIONS: GH administration in HF patients was associated with increased LVEF function. Several randomized clinical trials are necessary proving this relation. This trial is registered with IRCT201704083035N1.
BACKGROUND: The probable impact of growth hormone (GH) as a heart failure (HF) treatment strategy is still less investigated. Therefore, we aimed to evaluate the relation of 3-month GH prescription on left ventricular ejection fraction (LVEF), interventricular septum (IVS), posterior left ventricle (LV) thickness, end systolic and end diastolic diameters (ESD and EDD), and pulmonary arterial pressure (PAP) among Iranian individuals suffering from HF due to MI attack. METHODS: A total of 16 clinically stable participants with HF diagnosis and LVEF < 40% were selected for enrollment in this pilot randomized double-blinded study. They were randomly assigned equally to groups received 5 IU subcutaneous GH or placebo. Injections were done every other day for a total of 3-month duration. After termination of intervention and nine months afterwards, cardiac outcomes were assessed. RESULTS: Baseline and 12-month posttrial participants' characteristics were similar. LVEF was increased significantly by three months started from baseline in individuals receiving GH (32 ± 3.80% to 43.80 ± 4.60%, P = 0.002). During the next 9 months of follow-up concurrent with cessation of injections, LVEF was declined (43.80 ± 4.60% to 32.20 ± 6.97%, P = 0.008). LVEF and ESD were remarkably higher and lower in GH group compared with controls by the end date of injections (43.80 ± 4.60% vs. 33.14 ± 4.84%, P = 0.02 and 39.43 ± 3.45 mm vs. 33 ± 3.16 mm, P = 0.03, respectively). No other considerable association was found in terms of other predefined variables in neither GH nor placebo groups. CONCLUSIONS: GH administration in HF patients was associated with increased LVEF function. Several randomized clinical trials are necessary proving this relation. This trial is registered with IRCT201704083035N1.
Authors: Bernadette A Tumanan-Mendoza; Victor L Mendoza; April Ann A Bermudez-Delos Santos; Felix Eduardo R Punzalan; Noemi S Pestaño; Rudy Boy Natividad; Louie Alfred Shiu; Renelene Macabeo Journal: Heart Asia Date: 2017-03-27
Authors: Andrea Salzano; Alberto M Marra; Roberta D'Assante; Michele Arcopinto; Toru Suzuki; Eduardo Bossone; Antonio Cittadini Journal: Heart Fail Clin Date: 2018-08-17 Impact factor: 3.179
Authors: M Y Donath; G Sütsch; X W Yan; B Piva; H P Brunner; Y Glatz; J Zapf; F Follath; E R Froesch; W Kiowski Journal: J Clin Endocrinol Metab Date: 1998-09 Impact factor: 5.958
Authors: Kim Wadt Hansen; R Soerensen; M Madsen; J K Madsen; J S Jensen; L M von Kappelgaard; P E Mortensen; S Galatius Journal: BMJ Open Date: 2015-06-10 Impact factor: 2.692
Authors: Jarosław Wasilewski; Jacek Niedziela; Tadeusz Osadnik; Agata Duszańska; Wojciech Sraga; Piotr Desperak; Jolanta Myga-Porosiło; Zuzanna Jackowska; Andrzej Nowakowski; Jan Głowacki Journal: Kardiochir Torakochirurgia Pol Date: 2015-12-30
Authors: Alfredo De Giorgi; Alberto Maria Marra; Massimo Iacoviello; Vincenzo Triggiani; Giuseppe Rengo; Francesco Cacciatore; Ciro Maiello; Giuseppe Limongelli; Daniele Masarone; Francesco Perticone; Pasquale Perrone Filardi; Stefania Paolillo; Antonio Mancini; Maurizio Volterrani; Olga Vriz; Roberto Castello; Andrea Passantino; Michela Campo; Pietro Amedeo Modesti; Andrea Salzano; Roberta D'Assante; Michele Arcopinto; Valeria Raparelli; Fabio Fabbian; Angela Sciacqua; Annamaria Colao; Toru Suzuki; Eduardo Bossone; Antonio Cittadini Journal: Intern Emerg Med Date: 2022-04-21 Impact factor: 5.472